Miniatura

Fitxers

fimmu-14-1191782.pdf (4.16 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-08-04

Llicència de publicació

cc by (c) Navarro Compán, Victoria et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/208466

The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3389/fimmu.2023.1191782

Resum

Interleukin-17 family (IL-17s) comprises six structurally related members (IL-17A to IL-17F); sequence homology is highest between IL-17A and IL-17F, displaying certain overlapping functions. In general, IL-17A and IL-17F play important roles in chronic inflammation and autoimmunity, controlling bacterial and fungal infections, and signaling mainly through activation of the nuclear factor-kappa B (NF-kappa B) pathway. The role of IL-17A and IL-17F has been established in chronic immune-mediated inflammatory diseases (IMIDs), such as psoriasis (PsO), psoriatic arthritis (PsA), axial spondylarthritis (axSpA), hidradenitis suppurativa (HS), inflammatory bowel disease (IBD), multiple sclerosis (MS), and asthma. CD4(+) helper T cells (Th17) activated by IL-23 are well-studied sources of IL-17A and IL-17F. However, other cellular subtypes can also produce IL-17A and IL-17F, including gamma delta (gamma delta) T cells, alpha beta (alpha beta) T cells, type 3 innate lymphoid cells (ILC3), natural killer T cells (NKT), or mucosal associated invariant T cells (MAIT). Interestingly, the production of IL-17A and IL-17F by innate and innate-like lymphocytes can take place in an IL-23 independent manner in addition to IL-23 classical pathway. This would explain the limitations of the inhibition of IL-23 in the treatment of patients with certain rheumatic immune-mediated conditions such as axSpA. Despite their coincident functions, IL-17A and IL-17F contribute independently to chronic tissue inflammation having somehow non-redundant roles. Although IL-17A has been more widely studied, both IL-17A and IL-17F are overexpressed in PsO, PsA, axSpA and HS. Therefore, dual inhibition of IL-17A and IL-17F could provide better outcomes than IL-23 or IL-17A blockade.

Matèries

Malalties cròniques, Limfòcits, Psoriasi

Matèries (anglès)

Chronic Disease, Lymphocytes, Psoriasis

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

NAVARRO COMPÁN, Victoria, PUIG, Luis, VIDAL, Silvia, RAMÍREZ, Julio, LLAMAS VELASCO, Mar, FERNÁNDEZ CARBALLIDO, Cristina, ALMODÓVAR, Raquel, PINTO, José antonio, GALÍNDEZ AGUIRREGOIKOA, Eva, ZARCO, Pedro, JOVEN, Beatriz, GRATACÓS MASMITJÀ, Jordi, JUANOLA, Xavier, BLANCO, Ricardo, ARIAS SANTIAGO, Salvador, SANZ SANZ, Jesús, QUEIRO, Rubén, CAÑETE, Juan d.. The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases. _Frontiers in Immunology_. 2023. Vol. 14. [consulta: 2 de febrer de 2026]. ISSN: 1664-3224. [Disponible a: https://hdl.handle.net/2445/208466]

Exportar metadades

JSON - METS

Compartir registre